

SCOPE DEFINITION

Guideline Title: *Intrapartum fetal surveillance (IFS)*

Scope framework	
Population	<i>Which group of people will the guideline be applicable to?</i> Pregnant women during the intrapartum period
Purpose	<i>How will the guideline support evidence-based decision-making on the topic?</i> Identify relevant evidence related to: <ul style="list-style-type: none"> • Risk factors (antenatal and intrapartum) indicative of the need for IFS • Clinical surveillance during the intrapartum period
Outcome	<i>What will be achieved if the guideline is followed?</i> <i>(This is not a statement about measurable changes / not SMART goals)</i> Support: <ul style="list-style-type: none"> • Accurate assessment of antenatal and intrapartum risk factors • Implementation of best practice IFS protocols
Exclusions	<i>What is not included/addressed within the guideline</i> <ul style="list-style-type: none"> • Operation and maintenance of CTG machines • Antenatal fetal surveillance • Other methods of IFS <ul style="list-style-type: none"> ○ Computer assisted interpretation of CTG ○ ST segment analysis and fetal pulse oximetry ○ Fetal electrocardiogram including ST analysis ○ Fetal pulse oximetry ○ Near infrared spectroscopy ○ Short-term variability measurement • Elements specific to Queensland Clinical Guideline <i>Standard care</i> • Elements included in other Queensland Clinical Guidelines

Clinical questions

Question	Likely Content/Headings/Document Flow
Introduction	Communication
1. What factors may indicate an increased risk for intrapartum fetal compromise	<ul style="list-style-type: none"> • Antenatal risk factors • Intrapartum risk factors
2. What intrapartum fetal surveillance (IFS) recommendations are indicated for women with no risk factors?	<ul style="list-style-type: none"> • Intermittent auscultation <ul style="list-style-type: none"> ○ Indications ○ Modes (including equipment) ○ Auscultation ○ Frequency of monitoring ○ Management of abnormal findings
3. What IFS recommendations are indicated for women with risk factors?	<ul style="list-style-type: none"> • Cardiotocography <ul style="list-style-type: none"> ○ Indications ○ Admission cardiotocography (CTG) ○ Modes (External, telemetry, internal)
4. What is best practice with regards to CTG interpretation and subsequent action?	<ul style="list-style-type: none"> • Systematic method for interpretation • Review overall clinical picture • Frequency of review • Normal CTG features • Abnormal CTG features • Considerations for managing CTG: <ul style="list-style-type: none"> ○ Second stage of labour ○ Multiple pregnancy ○ Preterm labour ○ Intrauterine pressure catheter • Safety considerations • Management of abnormal CTG <ul style="list-style-type: none"> ○ Reversible causes ○ Further actions
5. What adjunct testing may support identification of a fetus at risk during the intrapartum period?	<ul style="list-style-type: none"> • Fetal blood sampling • Fetal scalp stimulation • Paired umbilical cord blood testing <ul style="list-style-type: none"> ○ Indications ○ Collection methods and timing ○ Cord blood values ○ Interpretation and reporting of results

Potential areas for audit focus (to be refined during development)

Audit items will relate to the desired outcomes and the clinical questions

- What proportion of women with identified risk factors were recommended a CTG during labour?
- What proportion of women without identified risk factors were recommended IA during labour?
- What proportion of women had CTG interpretation included in bedside handovers?
- What proportion of neonates had paired (arterial and venous) umbilical cord blood gas analysis taken after birth based on identified criteria?